Pulse.

a daily field guide to health research that matters

◆ Console

‹ Mon · 9 Nov 2026
Promising but preliminary

CEACAM5-Targeted Therapies in Solid Tumors: Biological Barriers and Next-Generation Precision Strategies.

Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) is an attractive therapeutic target because of its widespread overexpression in epithelial malignancies and its polarised, largely luminal expression in normal epithelium. Future patient selection should integrate CEACAM5 expression with target biology and therapeutic modality compatibility to identify patients likely to benefit and reduce ineffective treatment. © 2026 Ye et al.

Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) is an attractive therapeutic target because of its widespread overexpression in epithelial malignancies and its polarised, largely luminal expression in normal epithelium. Future patient selection should integrate CEACAM5 expression with target biology and therapeutic modality compatibility to identify patients likely to benefit and reduce ineffective treatment. © 2026 Ye et al.

What the study was

Study design
Narrative review
Category
Genomics/Precision Medicine
Maturity
Exploratory
Journal
Drug design, development and therapy

Why it surfaced

⚪ PROMISING_PRELIMINARY — Promising but preliminary; Watchlist: Precision oncology and genomic medicine, Novel therapeutics: immunotherapy, CAR-T, targeted therapy; Design: Narrative review (discusses Phase III CEACAM5 trial failure); species: human

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.